Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd (Ono), announced that the two companies have entered into a license agreement in whi...
Nxera Pharma has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (&...
Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white bloo...
Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...
Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences com...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...
The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...
Advanced Genomics APAC Co., Ltd. (hereinafter referred to as "Advanced Genomics APAC," headquartered in Taiwan, Managing Director: Andy Chang) is pl...
Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...
© 2025 Biopharma Boardroom. All Rights Reserved.
